SORLA’s Defense Against Tau Tangles
Researchers have identified two distinct proteins, SORLA and Arc, that play opposing roles in the progression of Alzheimer’s disease. While SORLA acts as a protective barrier against toxic tau protein accumulation, Arc functions as a carrier that facilitates the spread of toxic tau between neurons, according to findings reported in summer 2026.
New research published in Science Advances on July 17, 2026, highlights how the protein SORLA (sorting-related receptor with A-type repeats) helps the brain defend itself against Alzheimer’s pathology. Scientists at Sanford Burnham Prebys discovered that increasing levels of SORLA can suppress the formation of toxic tau tangles, a hallmark of neurodegenerative decline.
Under healthy conditions, tau stabilizes microtubules, the filament-like structures that help maintain neuronal shape and function. In disease, however, tau twists into toxic tangles that interfere with brain circuits. Timothy Huang, PhD, assistant professor in the Center for Neurologic Diseases at Sanford Burnham Prebys, noted the significance of the findings: In the last 15 or 20 years, considerable data has come out from our lab and other groups showing that SORLA can suppress one of the hallmarks of Alzheimer’s disease — amyloid-beta generation and accumulation. Very little was known, however, about whether SORLA affected the tau tangles reflected on the other side of the coin in Alzheimer’s disease.
Blocking the Mechanisms of Neurodegeneration
To investigate, the researchers crossbred mice that produce elevated levels of human SORLA with mice that develop tau tangles, brain atrophy, and cognitive deficits. The study found that higher SORLA levels interfered with several processes involved in tau tangle formation. Specifically, SORLA reduced the excessive addition of phosphate groups to tau, a process known as hyperphosphorylation. It also limited the ability of malformed tau to act as “seeds” that recruit more tau proteins and build larger clumps. The protective effects extended beyond tau itself; mice with more SORLA retained healthier synapses and showed better preservation of synaptic plasticity.
How Arc Acts as a Delivery Vehicle
While SORLA guards against disease, a separate study published in Cell on June 29, 2026, identifies a protein called Arc that may inadvertently assist in the disease’s advancement. Researchers at the University of Utah Health and Washington University in St. Louis found that Arc acts as a delivery vehicle for toxic tau, carrying it from diseased neurons to healthy ones through microscopic bubbles known as extracellular vesicles (EVs).
Mitali Tyagi, PhD, a postdoctoral research associate at Washington University in St. Louis, compared tau tangles to “glue monsters.” She explained: They glue together and block transportation within the neuron.
The research team studied a mouse model of Alzheimer’s disease in animals that either had Arc or lacked the protein. Their experiments showed that Arc plays an important role in allowing toxic tau to travel through the brain. Under normal conditions, Arc acts as a messenger between neurons, packaging itself inside extracellular vesicles that move between cells. Toxic tau appears able to attach itself to Arc and use this same delivery system to leave a diseased neuron and reach a healthy one.
The Risks of Therapeutic Inhibition
The research into Arc reveals a challenging biological trade-off. While Arc facilitates the spread of tau, it also acts as a pressure-release valve by helping sick neurons push excess tau outside. When Arc was missing in mouse models, more toxic tau stayed trapped inside the original neurons, causing those cells to die faster early in the disease.
The researchers also found vesicles containing both Arc and tau in human brain tissue. They observed that Arc levels in those vesicles rose alongside a disease-linked form of tau, though this does not yet prove the full process works the same way in living people. Because Arc is a central part of the transport route, researchers are cautious; a drug that switches Arc off everywhere could backfire by preventing neurons from clearing toxic buildup.
Future Paths for Clinical Research
Jason Shepherd, PhD, professor of neurobiology at University of Utah Health and senior author on the study, stated: I’m excited by the fact that we’ve identified a new way of potentially stopping the progression of Alzheimer’s disease.
These discoveries are currently limited to mouse models and laboratory settings and do not yet constitute a clinical treatment. The findings provide a granular understanding of how Alzheimer’s disease moves through the brain by mapping a specific step that researchers may be able to target. Patients and their families are encouraged to consult their healthcare providers regarding the latest developments in Alzheimer’s research and clinical trial availability.
Sources: Sciencedaily, Scitechdaily.
Keep reading